TREATMENT OF PSORIATIC ARTHRITIS WITH HOKT3Y1 (ALA-ALA)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 银屑病关节炎是一种慢性炎症性或肿胀型关节炎，大约7%的牛皮癣患者会发生这种关节炎。牛皮癣关节炎的病因尚不清楚。研究表明，一种被称为T细胞的特殊类型的白细胞可能与牛皮癣和牛皮癣关节炎的发展有关。HOKT3 1(ALA-ALA)是一种能与T细胞结合并影响T细胞功能的新型药物(单抗)。这项试验将检查hOKT3 1(ALA-ALA)对银屑病关节炎患者的安全性和有效性，以及该药物影响免疫系统的方式。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Psoriatic arthritis is a chronic inflammatory or swelling type of arthritis that occurs in approximately 7% of people with the skin disorder psoriasis. The cause of psoriatic arthritis is not known. Studies have shown that a particular type of white blood cell know as T-cells may be involved in the development of psoriasis and psoriatic arthritis. hOKT3 1 (Ala-Ala) is a new drug (a monoclonal antibody) that binds to T-cells and affects there function. This trial will examine the safety and effectiveness of hOKT3 1 (Ala-Ala) in patients with psoriatic arthritis, as well as the way the medication affects the immune system.